Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 541-555

  Fasinu, Pius ^a   Choonara, Yahya E ^a   Khan, Riaz A ^b   Du Toit, Lisa C ^a   Kumar, Pradeep ^a   Ndesendo, Valence K M ^a   Pillay, Viness ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b QASSIM UNIVERSITY   (Saudi Arabia)

Author keywords

Computational molecular modeling; Computer aided drug design; CYP3A4 inhibitors; Cytochrome P450; Docking studies; Drug delivery; Drug metabolism; Kinetics; Oral bioavailability; Polymers

Indexed keywords

AURANTIIN; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; FELODIPINE; MACROGOL 7500; MACROGOL DERIVATIVE; NARINGENIN; POLY(METHYL METHACRYLATE); POLYLYSINE; QUERCETIN; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BIOMIMETICS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; HUMAN; HUMAN CELL; IC 50; INTESTINE CELL; LIVER MICROSOME; MICHAELIS CONSTANT; MOLECULAR DOCKING; MOLECULAR MODEL; QUANTITATIVE ANALYSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84872496756     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23382     Document Type: Article

References (53)

1. Cross DM, Bayliss MK. 2000. A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development. Drug Metabol Rev 32(2):219-240.
2. Davila JC, Rodriguez RJ, Melchert RB, Acosta D. 1998. Predictive value of in vitro model systems in toxicology. Annu Rev Pharmacol Toxicol 38:63-96.
3. Ehrhardt C, Forbes B. 2005. Human respiratory epithelial cell culture for drug delivery applications. Eur J Pharm Biopharm 60(2):193-205.
4. Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wroghton SA. 2000. Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods 44(1):313-324.
5. Breedveld P, Beijnen JH, Schellens JH. 2005. Use of p-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmcol Sci 27(1):17-24.
6. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50(1):S41-S67.
7. Uwe F. 2000. Induction of drug metabolising enzymes: Pharmacokinetic and toxicological consequences in humans. Clin Pharm 38(6):493-504.
8. Fang X, Xiao-yin C. 2005. Effects of intestinal cytochrome P450 3A on phytochemical presystemic metabolism. Chin J Integr Med 11(3):232-236.
9. Zhang Y, Benet LZ. 2001. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and p-glycoprotein. Clin Pharm 40(3):159-168.
10. Nebert DW, Dalton TP. 2006. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947-960.
11. Guengerich FP. 2003. Cytochromes P450, drugs, and diseases. Mol Interv 3:194-204.
12. Gonzalez FG. 2005. Role of cytochromes P450 in chemical toxicity and oxidative stress: Studies with CYP2E1. Mutat Res 569(1-2):101-110.
13. Handschin C, Podvinec M, Amherd R, Looser R, Ourlin C, Meyer UA. 2002. Cholesterol and bile acids regulate xenosensor signalling in drug-mediated induction of cytochromes P450. J Biol Chem 277(33):29561-29567.
14. Rendic S. 2002. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metabol Rev 34(1):83-448.
15. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS, Brandt JT, Darstein C, Jakubowski JA, Salazar DE. 2007. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clinic Pharmacol Ther 81:735-741.
16. Cotreau MM, Moltke LL, Greenblatt D. 2005. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharm 44(1):33-60.
17. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruse MA, Haehner-Daniels B, Hall SD. 2003. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharm Ther 74:275-287.
18. Quintieri L, Palatini P, Nassi A, Ruzza P, Floreani M. 2007. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP3A4 and CYP3A5 enzymes. Biochem Pharmacol 75:1426-1437.
19. Dresser GK, Spence JD, Bailey DG. 2000. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38(1):41-57.
20. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. 2006. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
21. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. 2000. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interaction. Br J Clin Pharmacol 49(3):244-253.
22. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AYH. 2000. Human cytochrome P450 3A4: In vitro drug-drug interaction patterns are substrate dependent. Drug Metabol Dispos 28(3):360-366.
23. Masaoka Y, Tanaka Y, Kataoke M, Sakuma S, Yamashita S. 2006. Site of absorption after oral administration: Assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci 29(3-4):240-250.
24. Majundar S, Mitra A. 2006. Chemical modification and formulation approaches to elevated drug transport across cell membranes. Expert Opin Drug Deliv 3(4):511-527.
25. Leonard TW, Lynch J, McKenna MJ, Brayden DJ. 2006. Promoting absorption of drugs in human medium chain fatty acid-based solid dosage forms. GIPET Expert Opin Drug Deliv 3(5):685-692.
26. Hamman JH, Enslin GM, Kotze AF. 2005. Oral delivery of peptide drugs. Biodrugs 19:165-177.
27. Bailey DG, Arnold JMO, Spence JD. 1998. Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101-110.
28. Miniscalco A, Lundahl J, Regardh CG, Edgar B, Eriksson UG. 1992. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 261(3):1195-1199.
29. Ohshima H, Yoshie Y, Auriol S, Gilibert I. 1998. Antioxidant and pro-oxidant actions of flavonoids: Effects on DNA damage induced by nitric oxide, peroxynitrite and nitroxyl anion. Free Radic Biol Med 25(9):1057-1065.
30. Havsteen BH. 2002. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96(2-3):67-202.
31. Long A, Walker JD. 2003. Quantitative structure-activity relationship for predicting metabolism and modeling cytochrome P450 enzyme activities. Environ Toxicol Chem 22(8):1894-1899.
32. Sibeko B, Pillay V, Choonara YE, Khan RA, Modi G, Iyuke SE. 2009. Computaional molecular modeling and structural rationalization for the design of drug-loaded PLLA/PVA biopolymeric membrane. Biomed Mater 4:1-10.
33. Ironi L, Tentoni S. 2003. A model based approach to the assessment of physicochemical properties of drug delivery materials. Comput Chem Eng 27:803-812.
34. Rao S, Aoyama R, Schrag M, Trager WF, Rettie A, Jones JP. 2000. A refined 3-dimentional QSAR of cytochrome P4502C9: Computational predictions of drug integration. J Med Chem 43:2789-2796.
35. Rieko A. 2006. Computational models for predicting interactions with cytochrome P450 enzymes. Curr Top Med Chem 6(15):1609-1618.
36. Zhang T, Chen Q, Li L, Liu LA, Wei DQ. 2011. In silico prediction of cytochrome P450-mediated drug metabolism. Comb Chem High Throughput Screen 14:388-395.
37. Kirchmair J, Williamson MJ, Tyzack JD, Tan L, Bond PJ, Bender A, Glen RC. 2012. Computational prediction of metabolism: Sites, products, SAR, P450 enzyme dynamics, and mechanisms. J Chem Inf Model 52(3):617-648.
38. Herwaarden A, Waterschool RAB, Schinkel AH. 2009. How important is intestinal cytochrome P450 3A metabolism. Trends Pharmacol Sci 30(5):223-227.
39. Goosen TC, Cillie D, Bailey DG, Yu C, He K, Hollenberg PF, Woster PM, Cohen L, Williams JA, Rheeders M, Dijkstra HP. 2004. Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin Pharmacol Ther 76:607-617.
40. Yeo KR, Yeo WW. 2001. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human. Br J Clin Pharmacol 51:461-470.
41. Foster BC. 2001. An in vitro evaluation of human cytochrome P450 3A4 and p-glycoprotein inhibition by garlic. J Pharm Pharm Sci 4(2):176-184.
42. Celsis In Vitro Technologies. 2009. In vitro CYPTMM-class™ human liver microsomes. Accessed August 31, 2009, at: http://www.celsis.com/media/pdf/filelib/ps_InVitroCYPMclass.pdf.
43. Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, Shader RI. 1999. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 48(1):89-97.
44. Martinez C, Albert C, Agundez JAG, Herrero E, Carrillo JA, Márquez M, Benítez J, Ortiz JA. 1999. Comparative in vitro and in vivo inhibition of cytochrome P450: CYP1A2, CYP2D6 and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 65:369-376.
45. Schmider J, Von Moltke LL, Shader RI, Harmatz JS, Greeblatt J. 1999. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: Evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetin. Drug Metab Rev 31(2):545-560.
46. Yan G, Caldwell 2005. Evaluation of cytochrome P450 inhibition in human liver microsomes. Methods in Pharmacology and Toxicology, Optimization in Drug Discovery. In Vitro Methods. Totowa, New Jersey: Humana Press, pp. 231-244.
47. Cardoza RM, Amin PD. 2002. A stability indicating LC method for felodipine. J Pharm Biomed Anal 27(5):711-718.
48. Stoll B, Henry J, Reeds P, Yu H. 1998. Catabolism dominates the first-pass intestinal metabolism of dietary essential amino acids in milk protein-fed piglets. J Nutr 128(3):606-614.
49. Bikadi Z, Hazai E. 2009. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. J Cheminf 1:15.
50. Halgren TA. 1998. Merck molecular force field. I. Basis, form, scope, parametrization, and performance of MMFF94. J Comput Chem 17(5-6):490-519.
51. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. 1998. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639-1662.
52. Solis FJ, Wets RJB. 1981. Minimization by random search techniques mathematics of operations research 6: 19-30.
53. Toprakci M, Yelekci K. 2005. Docking studies on monoamine oxidase-B inhibitors: Estimation of inhibition constants (Ki) of a series of experimentally tested compounds. Bioorganic Med Chem Lett 15:4438-4446.